Tempest Therapeutics Adjourns Special Meeting After Failing to Secure Supermajority Vote on Governance Changes
TPST is trading near its 52-week low of $0.87 (1.1% below the low).
Summary
Tempest Therapeutics adjourned its special meeting to August 17 after failing to get the 75% supermajority vote needed to replace supermajority voting requirements and permit written consent. Only 67.7% of shares were voted, highlighting shareholder apathy or opposition amid severe financial distress.
Key Events · Corporate Governance and Compliance · TPST
-
Special Meeting Adjourned
The special meeting to vote on a charter amendment to replace supermajority voting requirements and permit stockholder action by written consent was adjourned to August 17, 2026, after failing to secure the required 75% supermajority vote.
-
Insufficient Vote Tally
Only 10,031,446 shares (67.7% of the 14,806,997 outstanding as of the May 28, 2026 record date) were voted, falling short of the 75% threshold needed for approval.
-
Governance Implications
The failure to pass this governance proposal signals weak shareholder engagement or opposition, potentially complicating future capital-raising efforts and corporate actions at a time when the company faces a going concern warning and Nasdaq listing deficiencies.
-
Next Steps
The reconvened meeting will be held virtually on August 17, 2026. No changes have been made to the proposal, and proxies already submitted remain valid unless revoked.
Analysis · TPST · Life Sciences
Tempest Therapeutics failed to get enough votes to amend its charter to remove supermajority voting requirements and allow stockholder action by written consent. Only 67.7% of shares were voted, short of the 75% supermajority needed. The meeting is adjourned to August 17, 2026. This is a governance red flag — the company cannot even rally enough shareholder support for a proposal that would make it easier to pass future measures, including potential capital raises. With a market cap near $14 million, a going concern warning, and recent Nasdaq deficiency notices, the inability to streamline governance adds operational friction at a critical time.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1993 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPST was trading at $0.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.9M. The 52-week trading range was $0.87 to $12.23. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.